Lungpacer Medical

Lungpacer Medical is a commercial-stage medical device innovator with a FDA PMA-approved product, the AeroPace System, for temporary transvenous diaphragm neurostimulation. The technology is clinically proven to accelerate weaning from mechanical ventilation, reduce ICU days, and lower risks of reintubation and tracheostomy in difficult-to-wean patients. With recent CMS NTAP approval enhancing reimbursement, the company is positioned to penetrate the large critical care ventilator weaning market while developing next-generation continual stimulation therapies.

Temporary transvenous diaphragm neurostimulation (TTDN) via a catheter-based system to pace the phrenic nerves, prevent diaphragm atrophy, and accelerate weaning from mechanical ventilation.

Lungpacer's AeroPace System appears first-in-class for temporary transvenous diaphragm pacing. Primary competition comes from standard-of-care weaning protocols (sedation vacations, spontaneous breathing trials) and possibly surgical diaphragm pacemakers for chronic conditions. It faces indirect competition from other therapies aimed at reducing ICU length of stay or treating critical illness myopathy.